News

Glonghui, February 10th｜British pharmaceutical giant AstraZeneca announced its 2025 results, with total annual revenue reaching $58.739 billions, an 8% year-on-year increase at constant exchange rates, mainly driven by growth in oncology, cardiovascular, and rare disease business segments; among them, product sales amounted to $55.573 billions, a 9% year-on-year increase; core earnings per share were $9.16, up 11% year-on-year. For the fourth quarter of 2025, total revenue was $15.503 billions, a 2% year-on-year increase; core earnings per share were $2.12, down 2% year-on-year. AstraZeneca CEO Pascal Soriot stated: "In 2025, the company achieved strong commercial performance across all therapeutic areas, and the R&D pipeline progressed smoothly. The company announced 16 positive Phase III clinical trial results and currently has 16 blockbuster drugs. Looking ahead to 2026, the company will continue to maintain its growth momentum and expects to announce results from more than 20 Phase III clinical trials this year." The company announced a second interim dividend of $2.17 per share; the total dividend for 2025 increased by 3% to $3.2 per share. Looking ahead to 2026, AstraZeneca expects total revenue to achieve mid-to-high single-digit percentage growth, and core earnings per share to achieve low double-digit percentage growth.

BlockBeats news, on February 10, Cobo co-founder and CEO Shenyu shared his investment insights on the X platform: "The biggest structural advantage individual investors have over institutions is not information or capital, but 'not having to answer to anyone.' He pointed out that funds are subject to institutional constraints such as LP requirements, drawdown limits, and quarterly assessments, which often force them to cut losses and exit at the worst possible times; whereas individual investors can take advantage of volatility and extend their investment horizon, picking up chips passively sold due to institutional constraints at market bottoms, thereby generating returns."

Over the past two years, the international benchmark price of low-purity gallium in Rotterdam has nearly tripled. Data shows that the average price in January this year reached a historic high of approximately 1,572 per kilogram. Gallium is widely used in global technology and military sectors, and China accounts for more than 90% of the world's primary production, holding an almost absolute dominant position. To reduce dependence on imports, the government has invested hundreds of millions in relevant domestic and foreign factories in recent months, aiming to reshape the global supply chain through a "gallium mining" strategy that combines local construction, cross-border cooperation, and recycling. It is predicted that by 2030, global demand for gallium will increase by about 24%.